Milmag

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Milmag

Quick Facts

Feature Detail
Active Ingredient Magnesium hydroxide or Magnesium lactate
Drug Class Laxative (for constipation) or Antacid (for indigestion)
Mechanism of Action Osmotic effect (laxative); Acid neutralization (antacid)

Milmag is a prescription or over-the-counter (OTC) medication primarily used in the management of gastrointestinal conditions, depending on its specific formulation. The name is generally associated with products containing a form of magnesium salt as the active ingredient.

Historically and in certain current formulations, the active substance in Milmag is magnesium hydroxide, which acts either as a laxative or an antacid. As a laxative, magnesium hydroxide draws water into the intestines through osmosis, which softens the stool and promotes bowel movements. In lower doses, it functions as an antacid by neutralizing hydrochloric acid in the stomach to relieve heartburn and indigestion.

Other formulations marketed under the Milmag brand or similar names may contain magnesium lactate. Magnesium lactate is a mineral supplement form that is generally well-absorbed and may be prescribed to treat or prevent low magnesium levels in the body, which are essential for nerve, muscle, and heart function.

Due to varying formulations globally, patients should always verify the specific active ingredient and intended use of their prescribed or purchased Milmag product with a healthcare provider or pharmacist.

Regulatory References

  1. NIH MedlinePlus on Magnesium Hydroxide

What side effects are possible with Milmag?

Possible Side Effects and Safety Information

Milmag's official safety profile, based on regulatory documentation, is characterized by two main categories of risk: common gastrointestinal effects and the potential for serious systemic toxicity (hypermagnesemia). The adverse reactions are classified across several System-Organ Classes (SOCs), primarily affecting Gastrointestinal disorders and Metabolism and nutrition disorders.


Adverse Reaction Frequency

Classification Examples of Officially Documented Effects
Common Diarrhea, abdominal cramps, and soft stools are commonly observed, reflecting the osmotic action of magnesium salts.
Very Rare Fatigue has been documented in cases involving high doses and prolonged administration of magnesium lactate.
Not Known Hypersensitivity reactions, including urticaria and anaphylaxis, have been documented but their frequency is unclassified.

Serious Adverse Reactions and Safety Constraints

The most clinically significant safety concern is Hypermagnesemia (magnesium toxicity), which is rare at standard doses in healthy individuals. Regulatory sources document that severe toxicity can lead to systemic effects, including a fall in blood pressure, respiratory depression, and cardiac arrest. Additionally, Intestinal obstruction or ileus are noted as serious risks, particularly with high doses in susceptible patients.

Population-Specific Safety: The medicine is explicitly contraindicated in individuals with severe renal impairment due to the high risk of magnesium accumulation and subsequent toxicity. Caution is also advised when administering to young children and infants due to their increased susceptibility to hypermagnesemia. These constraints define the limits of safe use, ensuring the risk of accumulation is officially minimized.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Milmag (Magnesium Salts)

Overdose with Milmag, which contains magnesium salts, is documented in official regulatory information to result in hypermagnesemia, or excessive magnesium concentration in the blood. The clinical manifestations of this state are progressive, primarily affecting the nervous and cardiovascular systems, as described in regulatory documents.

Documented Manifestations Severe Outcomes
Early Signs: Hypotension, nausea, vomiting, drowsiness, facial flushing, and depressed deep tendon reflexes. Life-Threatening: Respiratory paralysis, profound hypotension, complete heart block, and cardiac arrest.

Emergency Action Requirements

In cases where severe symptoms are present, such as respiratory distress, profound weakness, or significantly low blood pressure, official labeling mandates that individuals seek immediate medical attention and contact emergency services immediately. The prompt diagnosis and management of hypermagnesemia are critical.

Population Risk Note: Patients with impaired renal function are specifically documented in regulatory texts to be at a heightened risk of developing severe hypermagnesemia, as they are less able to clear excess magnesium from the body.

Officially Described Supportive Measures:

  • Management requires discontinuation of Milmag and initiating supportive and symptomatic treatment.
  • The effects of severe toxicity are officially documented to be antagonized by the administration of intravenous calcium salts.
  • Hemodialysis is listed as a potential required intervention for severe hypermagnesemia, particularly in the presence of kidney impairment, often alongside mandatory hospital monitoring of vital signs.

Therapeutic Uses of Milmag

What Milmag Treats: Main Uses and Benefits

Milmag is a magnesium supplement used for managing symptoms associated with low systemic magnesium. Such supplements are commonly used to manage associated symptoms and are generally applied across domains where additional symptomatic support is needed to help restore comfort and daily stability.

Therapeutic Focus Areas

The supplement may assist with symptoms related to muscle discomfort (such as involuntary cramps and spasms), fatigue and weakness, and nervous system distress (including irritability and tension). It is relevant in contexts marked by temporary physiological imbalance and when symptoms create noticeable physiological strain.

“This supplement supports patients during episodes of heightened discomfort by easing the overall symptom load.”

By helping to manage these manifestations, Milmag contributes to easing the overall symptom load and supports general well-being.


Quick Fact: Relief for Muscular and Nervous Symptoms Milmag is commonly used to help with symptoms that cluster into patterns requiring supportive management, focusing on easing physical discomfort and promoting a sense of calm.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Milmag — Official Regulatory Information

The official eligibility for Milmag, which contains a magnesium salt, is primarily defined by the state of the user’s kidney function and age, as documented in government regulatory sources (FDA/EMA).


Eligibility Category Regulatory Status
Contraindicated Populations Patients with severe renal failure or known hypersensitivity to the formulation.
Conditional Use Patients with any degree of kidney disease, those with acute gastrointestinal symptoms (e.g., stomach pain, vomiting), or patients on a magnesium-restricted diet.

Age-Related Eligibility Rules

Adults and adolescents 12 years and older are generally eligible for standard labeled use. Use in children under 12 years is limited and for certain multi-ingredient formulations, safety and effectiveness have not been established in those under 18 years of age.

Pregnancy and Lactation Status

Official labeling advises that a health professional must be consulted before use during pregnancy or lactation. Use during pregnancy is generally avoided unless the benefit clearly outweighs the risk, as documented in regulatory safety summaries.


Connection to the overall eligibility profile

Regulatory documents establish absolute contraindications for populations where the risk of magnesium toxicity is highest, notably those with severe kidney impairment. For all other populations, eligibility is conditional, requiring professional consultation for pediatric use and during pregnancy or breastfeeding, thereby restricting use to groups with an established safety profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Milmag, as a magnesium salt, has an official interaction profile primarily defined by its potential to physically interfere with the absorption of other oral medications and its risk of additive pharmacodynamic effects, as documented by regulatory authorities.

Documented Interaction Patterns

The most common interaction is a reduced systemic exposure of co-administered oral medicines, a documented pharmacokinetic interaction resulting from the magnesium component altering gastrointestinal pH or binding (chelation) to the other substance. Medicines affected by this include the antibiotic classes fluoroquinolones and tetracyclines, as well as bisphosphonates, and thyroid hormones (e.g., levothyroxine).

This required pharmacokinetic constraint is addressed by a mandatory timing rule in regulatory labels, which specifies that many oral medications must be administered at least two hours before or after Milmag.

Pharmacodynamic and Population Cautions

A second significant interaction is the risk of hypermagnesemia, an additive pharmacodynamic effect documented when Milmag is taken alongside other magnesium-containing preparations (such as other antacids or laxatives). Regulatory documents explicitly state that this risk of magnesium accumulation and severe toxicity is substantially heightened for patients with renal dysfunction (impaired kidney function) due to reduced clearance.

Mechanism of Action

Milmag is an alkyl-lysophospholipid analogue that exerts its effects through multiple intracellular targets. The primary mechanism involves cellular membrane disruption. The compound incorporates into the plasma and mitochondrial membranes, altering their structural integrity and fluidity. This physical modification leads to a cascade of cellular dysfunction.

At a molecular level, Milmag functions by inhibiting the synthesis of phosphatidylcholine, a critical component of lipid membranes. This inhibition disrupts the cell's ability to maintain and repair its structure. Furthermore, the compound interacts with the cell’s energy pathways by inhibiting cytochrome c oxidase within the mitochondrion, leading to an immediate decline in adenosine triphosphate (ATP) production. An additional downstream effect includes the activation of a sphingosine-dependent calcium ion (Ca^2+) channel on the plasma membrane, which triggers an uncontrolled influx of Ca^2+ ions. The combination of membrane permeabilization, energy deprivation, and ionic imbalance results in a defined pattern of cellular disassembly.

Dosage and Administration Information

The administration of Milmag is governed by the product’s specific active ingredient and its intended use as a laxative, antacid, or systemic supplement. The designated route of administration is oral. Dosage, frequency, and duration are specific to the intended use.

Indication Adult Dosing Pattern Key Instruction
Laxative Use High-level doses (e.g., 2,400 mg to 4,800 mg) are generally taken once daily or in divided doses. Must be taken with a full glass of liquid; use is limited to a maximum of 7 days.
Antacid Use Lower doses (e.g., 400 mg to 1,200 mg) are taken as needed, up to four times per day. Use is typically limited to a maximum of 14 consecutive days.
Supplementation Elemental magnesium doses (e.g., 84 mg) are often administered every 12 hours or 2-3 times daily. Modified-release forms may be specified to be taken with food.

For all liquid suspensions, the container must be shaken well before the dose is measured, and calibrated measuring tools must be used. A critical administration constraint across all forms is the requirement to administer Milmag at least two hours before or after taking other oral medications to prevent interference with drug absorption. Dose adjustments for patients with renal impairment are specified in labeling and must be followed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Milmag

Evidence for Use as a Laxative (Magnesium Hydroxide Formulation)

Research has explored Milmag's role as a laxative in conditions associated with functional constipation. This evidence includes short-term Randomized Controlled Trials (RCTs) and controlled studies that research examined how outcomes related to functional imbalance are affected. These studies monitored changes in bowel movement frequency and stool consistency over defined time intervals.

Findings describe patterns observed in the studies where the agent was associated with changes in bowel function over the short term. Some trials explored how it was studied against other agents, such as polyethylene glycol (PEG). Research highlights changes measured during the study period, focusing on acute or episodic symptom patterns.

Evidence is limited regarding long-term outcomes. The research does not determine whether an individual will respond similarly, as results apply only to the populations studied. Follow-up durations were limited, and acceptance and tolerability, particularly in pediatric groups, were often measured as secondary outcomes.

Evidence for Use as an Antacid (Magnesium Hydroxide Formulation)

The evidence base for addressing symptoms of indigestion and heartburn is defined by acute clinical studies and laboratory measurements. Research was studied for how rapidly the agent can neutralize acid in the stomach. Studies evaluated the agent's acid neutralization capacity.

Studies report how symptoms evolved in the observed populations over very short timeframes. Data show patterns related to a rapid, temporary increase in gastric pH. Studies observed the acid neutralization capacity. However, many of the core findings was observed in studies involving the agent in combination with other antacid ingredients.

There is limited information for long-term outcomes. Evidence for use in daily maintenance or prevention for chronic conditions is limited. Research provides limited insight into the agent's use alone for chronic, daily management.

Evidence for Supportive Supplementation (Magnesium Lactate Formulation)

The research was evaluated in supplementation trials to address symptoms associated with low magnesium status, such as outcomes related to physical discomfort. RCTs and observational studies were used in research exploring how symptoms change over time, measuring both biomarker shifts and patient-reported outcomes describing perceived discomfort.

Research involving bioavailability measurements documented the absorption of magnesium lactate when compared to certain other magnesium salts. Trials reported that supplementation was associated with measurable changes in serum magnesium and RBC magnesium levels in observed populations. Regarding specific outcomes related to physical discomfort, findings were mixed and evidence quality varies across studies.

Key Studies & References

  1. Magnesium: Uses, Side Effects, Interactions, Dosage, and Warning

Frequently Asked Questions (FAQ)

Common questions about Milmag (FAQ)


Q: Is Milmag the same as magnesium supplements sold over the counter?

A: Milmag is available in formulations that are sold over-the-counter (OTC) for its uses as a laxative and antacid, and other forms may be prescription-only. The key difference often involves the specific magnesium salt it contains (like magnesium hydroxide versus magnesium lactate) and the specific medical use defined on the product's official regulatory label.


Q: Can Milmag be taken with vitamins or other daily supplements?

A: Official administration guidelines advise that Milmag should be taken at least two hours before or two hours after taking other oral medicines, including certain supplements and vitamins. This timing separation is specified in regulatory guidelines to help minimize the potential for Milmag to interfere with the absorption of other substances.


Q: What should I do if the listed side effects seem minor but they bother me?

A: Regulatory guidance indicates that if minor side effects persist, worsen, or cause concern, consultation with a health professional is advised. This step is defined to allow a provider to assess the symptoms and determine the appropriate path forward.


Q: Does Milmag start working immediately, or does it take a few days?

A: The time it takes for Milmag to work depends on its intended purpose. When used as an antacid, the effect of neutralizing stomach acid is typically very fast. When used as a laxative, the onset of a bowel movement is generally described in regulatory labels as occurring within 30 minutes to 6 hours after administration.


Q: What happens if I forget to take Milmag one time?

A: Official administration instructions generally state that if a dose is missed, you can take it as soon as you remember. However, if it is almost time for the next scheduled dose, the missed dose should typically be skipped, and your regular schedule resumed. Official documentation advises against taking double or extra doses.


Q: Is it normal to feel a bit tired when starting Milmag?

A: Fatigue or drowsiness is noted in some regulatory safety profiles, but it is more commonly documented with higher doses or prolonged administration. It is not typically listed as a common, transient effect when a person initially starts treatment at standard doses.


Q: Can Milmag affect my sleep, making it harder to fall asleep?

A: The active ingredient, magnesium, is involved in neurological functions. However, specific effects on sleep are not listed as common adverse reactions on the regulatory product labels for Milmag.


Q: Are there any foods I absolutely must avoid while taking Milmag?

A: Regulatory documents caution individuals with pre-existing kidney impairment to avoid using magnesium salts alongside foods or beverages containing citric acid (citrates). This is due to the potential for increased magnesium absorption. Regulatory documents do not typically specify this restriction for individuals without kidney impairment.


Q: Can Milmag cause changes in mood or anxiety levels?

A: While severe magnesium toxicity (hypermagnesemia) is documented to cause changes to the central nervous system, such as confusion or lethargy, general changes in mood or anxiety are not typically listed as common adverse reactions on standard regulatory labels for Milmag.


Q: How does Milmag compare to other medications used for the same condition?

A: Official classifications describe Milmag as belonging to the saline laxative and antacid drug classes. This classification refers to its mechanism of action, which involves drawing water into the intestine or directly neutralizing stomach acid, distinguishing it from other types of medicines like bulk-forming laxatives or proton pump inhibitors.


Q: Is the research on Milmag considered strong and reliable?

A: The official overview highlights that evidence describes patterns related to short-term outcomes in studied populations. Findings related to long-term use and specific patient-reported outcomes may be described as limited or mixed. Regulatory documentation focuses on what the studies measured rather than giving a judgment on overall reliability.


Q: Can Milmag affect the results of blood tests?

A: Yes, Milmag contains magnesium, which is an important electrolyte. Taking high doses of Milmag can potentially lead to elevated magnesium levels in the blood, known as hypermagnesemia, which can be detected by blood tests. This potential is a specific safety concern for those with impaired kidney function.


Q: What are the official guidelines for stopping Milmag if a person feels better?

A: Official guidelines emphasize that Milmag, when used as a laxative or antacid, is intended for short-term, acute relief with defined maximum duration limits. These time limits defined in regulatory guidelines indicate that the medication is intended for acute use, restricting long-term use unless directed by a health professional.


Q: Is Milmag a kind of electrolyte replacement?

A: Milmag, which contains a magnesium salt, is officially classified as a laxative and an antacid based on its primary uses. While magnesium is an electrolyte that can be used to treat deficiency, this specific product is not classified solely as an electrolyte replacement across all its labeled indications.


Q: Does Milmag have a 'half-life' that I should know about?

A: The official product information addresses how the body eliminates the absorbed magnesium component, which is mainly done through the kidneys. While 'half-life' is a specific technical term used in pharmacology, it is generally discussed in the clinical pharmacology section and not typically highlighted in patient-facing instructions.


Q: If I am taking Milmag for a long time, do I need regular blood checks?

A: Regulatory documents explicitly advise that patients with existing renal (kidney) impairment are at a higher risk of magnesium accumulation. For these individuals, clinical monitoring of serum magnesium levels is often a recommended precaution.


Q: Is it necessary to drink extra water when taking Milmag?

A: For its use as a laxative, official administration instructions generally specify that each dose should be followed by a full glass of liquid. This is a key instruction specified on the label to support the drug's osmotic action and help maintain hydration.


Q: What is the difference between Milmag and other forms of the same ingredient?

A: The official labeling defines various available forms, such as liquid suspensions, chewable tablets, or capsules. These forms may differ in their specific active magnesium compound, concentration, release profile, and the officially approved indications (laxative versus antacid).


Q: Can I take Milmag if I am currently breastfeeding?

A: Official information advises consulting a health professional before using Milmag while breastfeeding. Studies have indicated that when used by the mother, magnesium hydroxide is not expected to significantly affect the serum magnesium levels of the breastfed infant due to its poor absorption into the milk.


Q: Why is it important to avoid certain antacids while taking Milmag?

A: Regulatory documents warn against taking Milmag alongside other preparations that contain magnesium, such as certain antacids or laxatives. This is due to the potential for an additive pharmacodynamic effect that increases the risk of magnesium accumulation and subsequent systemic toxicity (hypermagnesemia).


Q: How does the body eliminate Milmag after it's been taken?

A: Any portion of the active magnesium component of Milmag that is absorbed into the bloodstream is primarily eliminated from the body by the kidneys. This process is detailed in the clinical pharmacology section of the official drug label.


Q: Do children react differently to Milmag compared to adults?

A: Regulatory documents explicitly caution that children, particularly young children and those with renal impairment, have an increased susceptibility to hypermagnesemia (magnesium toxicity) compared to adults. Use in children requires professional medical advice and careful monitoring.


Q: What if I experience a rare but non-serious side effect from Milmag?

A: The official safety documentation classifies side effects by frequency, from common to very rare. Regulatory guidance advises patients to consult with a health professional if any side effects occur and cause concern, regardless of how frequently they are classified.


Q: Is Milmag effective for symptoms other than the primary condition it treats?

A: The official indications for Milmag are limited to the primary condition it is approved to treat: constipation, indigestion, or magnesium deficiency. Regulatory documents do not address or support the use of the drug for any other symptoms or conditions.


Q: Does Milmag affect blood pressure in general?

A: While a severe case of magnesium toxicity can cause a significant fall in blood pressure, the official drug label does not typically cite a general, non-toxicological effect on blood pressure for standard use. The official drug label does not typically cite a general, non-toxicological effect on blood pressure for standard use.


Q: What happens if Milmag is taken on an empty stomach?

A: For its use as an antacid, the regulatory label often specifies that Milmag can be taken as needed. The laxative effect is generally more pronounced and faster when taken on an empty stomach due to quicker transit through the digestive system, though some specific forms may require administration with food.


Q: Can Milmag make me constipated or cause diarrhea?

A: Diarrhea and abdominal cramps are listed in the official safety profile as common adverse reactions, which reflects the drug’s osmotic action. The product label for Milmag as a magnesium salt used for laxative purposes does not list constipation as an expected side effect.

How should Milmag be stored and disposed of?

Storage and Disposal of Milmag (Magnesium Hydroxide Liquid)

The official labeling for Milmag, which contains a magnesium salt, requires specific conditions for storage and disposal to maintain product integrity and safety.


Storage Requirements

Condition Requirement
Temperature Store at room temperature, between 20° to 25°C (68° to 77°F).
Freezing Avoid freezing the product to prevent degradation.
Protection Keep the container tightly closed in its original packaging to protect the contents from moisture.
Child Safety Keep Milmag out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired Milmag, regulatory guidelines recommend utilizing a drug take-back program or an authorized collection point. If a take-back option is unavailable, the alternative is to mix the medicine with an undesirable substance, secure it in a sealed bag, and discard it in the household trash. The product should not be poured down the sink or flushed into the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Milmag found in:

A-Z Index: